Go to deals
Healthcare

Xbrane Biosciences AB has aquired Primm Pharma

Xbrane Biosciences AB (Xbrane) has acquired Primm Pharma (Primm) for an undisclosed consideration.

Based in Sweden, Xbrane is a biopharmaceutical company specialized in high demand complex generics. This segment has a high entry barrier, driven by high production complexity and the need of specific know-how. The company is looking to extend its offering within the protein production and to gain access to new sales channels through the acquisition of biotech companies offering products and/or services within the protein biosynthesis production chain.

Primm is an international leading company engaged in the manufacturing, marketing and sale of biotech services and products. The company provides advanced custom services like antibodies, peptides, DNA synthesis, DNA sequencing, protein analysis and a variety of pharmacological services based on the use of a state-of-the-art animal facility recently certified under the international GLP standards. Primm was founded in 1990 and is headquartered in Milan, Italy.

Oaklins' teams in Sweden and Italy supported the buyer by scouting the Italian market, identifying the most suitable target, assisting in the LOI formulation and negotiation throughout the process. This deal is another example of seamless cooperation between Oaklins' teams, demonstrating the organization’s added value through its global execution capabilities, industry expertise and contacts.

Parties

Talk to the deal team

 Adel  Koubaa

Adel Koubaa

Managing Partner
Stockholm, Sweden
Oaklins Sweden
 Giuseppe Maria Bernardo  Puccio

Giuseppe Maria Bernardo Puccio

Principal
Milan, Italy
Oaklins Italy
 Lars  Gustafsson

Lars Gustafsson

Partner
Stockholm, Sweden
Oaklins Sweden
 Mariacristina  Lisi

Mariacristina Lisi

Senior Researcher
Milan, Italy
Oaklins Italy

Related deals

Prestige Inhome Care has found a long-term strategic partner
Healthcare

Prestige Inhome Care has found a long-term strategic partner

Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.

Learn more
Cara Care has been acquired by Mahana Therapeutics
Private Equity | Healthcare | TMT

Cara Care has been acquired by Mahana Therapeutics

Mahana Therapeutics Inc., renowned for its pioneering digital treatments targeting chronic health issues, has recently finalized the acquisition of Cara Care (HiDoc Technologies GmbH). Cara Care stands out as a premier digital health platform and an official digital health application (DiGA) dedicated to enhancing gut health. This acquisition, supported by key investors Lux Capital and Jazz Ventures Partners, perfectly aligns with Mahana’s expansion strategy.

Learn more
Apotheka acquires two pharmacy outlets from Panpharmacy
Consumer & Retail | Healthcare

Apotheka acquires two pharmacy outlets from Panpharmacy

In a strategic move that signifies the ongoing consolidation and growth within the Latvian pharmaceutical retail sector, Panpharmacy, the parent company of the leading online pharmacy InternetAptieka.lv, has successfully completed the sale of two of its brick-and-mortar pharmacies to Apotheka. These pharmacies, both situated in the capital city of Riga, will continue to serve customers under the Apotheka brand, marking a seamless transition in ownership and operations.

Learn more